Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • Evidence of autoimmunity’s origins uncovered via new approach

    Autoimmune diseases are thought to be the result of mistaken identity. Immune cells on patrol, armed and ready to defend the body against invading pathogens, mistake normal human cells for infected cells and turn their weapons on their own healthy tissues. In most cases, though, finding the source of the confusion the tiny fragment of normal human protein that looks dangerously similar to a protein from a pathogen  has been challenging for scientists.

  • Antiviral defence regulates intestinal function and overall gut health

    Besides the skin, the digestive tract is the tissue that is most exposed to environmental influences such as bacteria and viruses. Therefore, cells that form these barriers to the interior of the body also have special defence mechanisms. A research team led by Professor Dr Thorsten Hoppe has now shown that RNA interference, or RNAi for short, which is known to be a viral defence mechanism, also prevents the overproduction of the body’s own proteins in intestinal cells.

  • Study Shows Promise of New Anti-KRAS Drug for Pancreatic Cancer

    A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.

  • How Metastatic Cancer Causes Leaky Blood Vessels

    Preventing metastasis – the development of cancer cells beyond their original location – remains one of the major goals of current cancer research. Most malignant tumor cells metastasize by exploiting abnormal leakage from blood vessels. New work looks to further explore the role of how the alignment of endothelial cells, which line blood vessels, plays a role in the spread of cancer.

  • The off-patent drug that could protect us from future COVID-19 variants

    Scientists have identified a drug that can be repurposed to prevent COVID-19 in research involving a unique mix of ‘mini-organs’, donor organs, animal studies and patients.

  • Novartis Pluvicto shows free survival benefit in patients with prostate cancer

    Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. Pluvicto demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with PSMA–positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen-receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI1.

  • Peanuts and herbs and spices may positively impact gut microbiome

    Adding a daily ounce of peanuts or about a teaspoon of herbs and spices to your diet may affect the composition of gut bacteria, an indicator of overall health, according to new research from Penn State. In two separate studies, nutritional scientists studied the effects of small changes to the average American diet and found improvements to the gut microbiome.

  • Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach

    While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) shows new promise, according to data from a first-in-human clinical trial.

  • Neuroscientists discover a new drug candidate for treating epilepsy

    Temporal lobe epilepsy (TLE) is one of the most common types of epilepsy worldwide. Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. A research team co-led by a City University of Hong Kong (CityU) neuroscientist recently identified and developed a new drug candidate that has potential for effectively treating TLE by suppressing neuroinflammation.

  • Chemotherapy could increase disease susceptibility in future generations

    A common chemotherapy drug could carry a toxic inheritance for children and grandchildren of adolescent cancer survivors, Washington State University-led research indicates.

Subscribe to Research News